KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Cash & Equivalents (2018 - 2025)

Historic Cash & Equivalents for Esperion Therapeutics (ESPR) over the last 8 years, with Q3 2025 value amounting to $92.4 million.

  • Esperion Therapeutics' Cash & Equivalents fell 3611.88% to $92.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $92.4 million, marking a year-over-year decrease of 3611.88%. This contributed to the annual value of $144.8 million for FY2024, which is 7600.55% up from last year.
  • Per Esperion Therapeutics' latest filing, its Cash & Equivalents stood at $92.4 million for Q3 2025, which was down 3611.88% from $86.1 million recorded in Q2 2025.
  • In the past 5 years, Esperion Therapeutics' Cash & Equivalents registered a high of $226.6 million during Q1 2024, and its lowest value of $82.2 million during Q4 2023.
  • Moreover, its 5-year median value for Cash & Equivalents was $144.7 million (2024), whereas its average is $146.6 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first surged by 7600.55% in 2024, then plummeted by 5453.82% in 2025.
  • Over the past 5 years, Esperion Therapeutics' Cash & Equivalents (Quarter) stood at $208.9 million in 2021, then plummeted by 40.27% to $124.8 million in 2022, then crashed by 34.08% to $82.2 million in 2023, then skyrocketed by 76.01% to $144.8 million in 2024, then crashed by 36.14% to $92.4 million in 2025.
  • Its Cash & Equivalents was $92.4 million in Q3 2025, compared to $86.1 million in Q2 2025 and $114.6 million in Q1 2025.